ascopubs.org

Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 ...

Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN No significant financial relationships to disclose. This ...
ascopubs.org

A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy

Does one person provide it all? Defining the social support of women with cancer Pts with adverse events - n (%) 46 (79) 49 (88) 95 (83) Pts with serious adverse events - n (%) 18 (31) 21 (38) 39 (34) ...
Nature

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Patients with low or intermediate-1 (int-1) International Prognostic Scoring System (IPSS) risk myelodysplastic syndromes (MDS) have a median survival of 5.7 and 3.5 years, respectively, when treated ...